Completed PHASE2 INTERVENTIONAL 6-arm NCT00879658

Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis

A Phase II, Double-blind, Randomized, Multi-center, Adaptive Dose-ranging, Placebo-controlled, Parallel-group Study Evaluating Safety, Tolerability and Efficacy on MRI Lesion Parameters and Determining the Dose Response Curve of BAF312 Given Orally Once Daily in Patients With Relapsing-remitting Multiple Sclerosis.

Sponsor: Novartis Pharmaceuticals

Conditions Relapsing-remitting Multiple Sclerosis

Interventions BAF312 Placebo

Updated 8 times since 2017 Last updated: Dec 26, 2019 Started: Mar 30, 2009 Primary completion: May 4, 2011 Completion: May 4, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Relapsing-remitting Multiple Sclerosis, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 8 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Feb 2020 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Feb 2020 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Ankara, Turkey (Türkiye) , Barcelona, Spain , Basel, Switzerland , Bergen, Norway , Berlin, Germany , Bern, Switzerland , Bilbao, Spain , Budapest, Hungary , Centennial, United States and 52 more locations